Full text

Turn on search term navigation

© 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background

Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors.

Aims

Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity.

Methods

We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy.

Results

Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases.

Conclusions

The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients.

Details

Title
Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
Author
Kucukyurt, Selin 1   VIAFID ORCID Logo  ; Yagiz Ozogul, Yeliz 2   VIAFID ORCID Logo  ; Ercaliskan, Abdulkadir 1   VIAFID ORCID Logo  ; Kabasakal, Levent 3   VIAFID ORCID Logo  ; Eskazan, Ahmet Emre 1   VIAFID ORCID Logo 

 Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University‐Cerrahpasa, Istanbul, Turkey 
 Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University‐Cerrahpasa, Istanbul, Turkey 
 Department of Nuclear Medicine, Cerrahpasa Faculty of Medicine, Istanbul University‐Cerrahpasa, Istanbul, Turkey 
Section
CASE REPORTS
Publication year
2020
Publication date
Oct 1, 2020
Publisher
John Wiley & Sons, Inc.
e-ISSN
25738348
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3090225110
Copyright
© 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.